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Abstract 
 
Background:  To determine the optimal dose of 
antisnake venom required to treat hemotoxic snake bite 
more effectively. 
Methods: In this interventional study, out of 52 patients 
46 patients with  the features of systemic envenomation 
.i.e. deranged coagulation profile, nephrotoxic or 
neurotoxic features  were assessed clinically and through 
laboratory tests, while 06 patients had no feature of 
envenomation. Patients with systemic envenomation were 
given Antisnake venom.  
Results: Hemotoxicity was the most common clinical 
manifestation of snake bite i.e. 39 patients of hemotoxic 
envenomation, 4 with neurotoxic features while 03 patients 
had mixed toxicity i.e. hemotoxic, neurotoxic and 
nephrotoxic. 12 patients responded to single dose of 06 
vials (10 ml each vial; total dose of 60 ml), 28 patients 
required further dose of anti snake venom  after initial 
dose of 6 vials  while 06 patients received even higher dose 
of anti snake venom  i.e. 18 vial (180 ml) with blood 
transfusion.  Of these 06 patients, 02 required mechanical 
ventilation, 02 with nephrotoxicity were referred to 
dialysis unit, and 02 mortalities were encountered, one 
with intracranial bleed and other with mixed toxicity and 
delayed presentation of patient. 
Conclusion: Most patients with envenomation require 
higher dose of anti snake venom . An increase in 
morbidity and mortality is mainly due to delayed 
presentation after snake bite and under dosage of ASV. 
Key Words:   Snake bite, Snake venom, Hemotoxic, 
Envenomation. 
 
Introduction 
 
Snake  bite remains a public health problem in 
many countries even though it is difficult to be precise 
about the actual number of cases. It is estimated that 
the true incidence of snake envenomation could 
exceed 5 million per year, with nearly 50,000 deaths 
400,000 develop severe sequelae 1. The global disparity 
in the epidemiological data reflects variations in health 
reporting accuracy as well as the diversity of economic 
and ecological conditions 2. Accurate records to 
determine the exact epidemiology or even mortality in 
snake bite cases are also generally unavailable 3. 
Hospital records fall far short of the actual number 
owing to dependence on traditional healers and 
practitioners of witchcraft etc. It has been reported that 
in most developing countries, upto 80% of individuals 
bitten by snakes first consult traditional practitioners 
before visiting a medical centre 4,5. 
There are misconceptions concerning the level 
of snakebite prevalence and mortality in Pakistan, 
mainly published by international observers. Estimates 
are given of 20,000 snakebite deaths 6 and yet the 
Health Department morbidity and mortality figures 
from Tharparker District (Pop. 0.9 Million), with the 
most significant snakebite problem, in 2003 were 24.41 
and 1.1 respectively, per 100,000 7. 
 Approximately 15 percent of the 3000 species 
of snakes distributed world wide are venomous. Snake 
envenomation is termed technically as ophitoxemia 8-9. 
The main stay of treatment of snake bite is 
antisnake venom that neutralizes the venom. Type of 
ASV available in Pakistan is Liquid ASV provided by 
National Institute of Health Islamabad Pakistan 
Much has been written about the initial dose 
of ASV to be administered, most of which, such as the 
advice on the ASV product insert is completely 
misleading or incorrect 10. When determining dosage 
levels, particularly the initial dose of ASV, it is 
important to consider the amount of venom injected 
by the snake in an average bite. Russell's viper and 
cobra inject approximately 60mg of venom in the 
average bite. Each ASV vial neutralizes 6mg of cobra 
and Russell's viper venom and therefore the initial 
dose of ASV should be 8-10 vials in all cases with clear 
evidence of envenoming11. 
The objective of this study was to look into 
different clinical manifestations of snake bite in 
population of study area and to assess proper effective 
dose of antisnake venom in an attempt to establish 
local protocols.  
 
Patients  and Methods 
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This Hospital based study was carried out in 
District Headquarters Hospital (DHQ) Rawalpindi 
from April 2008 to July 2008. A total of 52 patients 
presenting in emergency department with history of 
snake bite were studied. .An inclusion criterion for 
patients in study was; history of snake bite i.e. eye 
witness account of snake bite, local features i.e. fangs 
marks, cellulitis, and patients with systemic features 
such as evidence of hemotoxicity i.e. bleeding 
tendency, deranged coagulation profile, prothrombin 
time (PT) more than 30 of normal, activated partial 
thromboplastin time (APTT) more than 30 of normal 
or platelets count <100,000 which were performed in 
hospital laboratory. Other investigations such as 
serum urea, creatinine, creatine phosphokinase (CPK), 
lactate dehydrogenase (LDH), were also done in all 
patients to look for nephrotoxic and myotoxic 
envenomation. Patients with features of neurotoxic 
features i.e. new onset of ptosis, dysphagia, nasal 
regurgitation, respiratory distress requiring 
mechanical ventilation were admitted in intensive care 
unit (ICU) where the facility of mechanical ventilation 
was available. Patients with clear features of systemic 
envenomation were given Antisnake venom.i.e. Poly 
valent liquid ASV (10 ml each vial) provided by 
National Institute of Health Islamabad Pakistan with 
well maintained cold chain.  
 Initial dose of 06 vials was given  in 500ml of 
normal saline over 2 hrs. After 6 hrs of ASV infusion, 
patients were reassessed clinically and through 
laboratory tests. In case of no improvement the same 
dose of ASV was repeated.  
The patients bleeding profusely were 
transfused with blood, platelets, or fresh frozen 
plasma accordingly in addition to ASV. Patients with 
evidence of nephrotoxicity i.e. markedly raised urea 
and creatinine, myotoxicity markedly raised LDH, and 
CPK (rhabdomyolysis) were referred to dialysis units.  
 
Results 
  
Out of 52 patients 28 (53.8%) presented within 
24 hrs, 16.30% presented within 48 hrs while 08 (1.5%) 
patients presented after 48 hrs of snake bite(fig 1). 
Most, 42 (80%) patients were male while 10 (20%) were 
female. Forty six  (88%) patients had the features of 
systemic envenomation while 6(12%) had no features. 
The most common clinical manifestation of snake bite 
found was hemotoxicity  (84.7%), followed by 
neurotoxicity (4 patients; 8.7%) , while 3 patients 
(6.5%) revealed mixed toxicity , i.e., hematotoxicity, 
neurotoxicity and nephrotoxicity(fig 2) . Twelve (26%) 
patients responded to single dose of 06 vials (60ml), 28 
(60.8%) patients required further dose of ASV after 
initial 6 vials i.e.  (120ml).  
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Fig1 : Duration of presentation after snake 
bite 
Six (13%) patients received higher dose of ASV 
180ml with blood and blood products(Fig 3)  
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Fig2: Nature of Snake Envenomation 
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Fig 3: Dose Response Relationship 
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Fig 4: Outcome of patients  
 
Out of total 46 envenomed patients 40 (86.9%) 
recovered. 02(4.3%) patients required prolonged 
mechanical ventilation and Intensive care but 
recovered. 02 (4.3%) patients with nephrotoxicity were 
referred to dialysis unit after giving initial dose of 
ASV(fig4).Two (4.3%) mortalities were encountered 
one (2.17%) with intracranial bleed and other (2.17%) 
with mixed toxicity and delayed presentation of 
patient.  
 
Discussion 
 
This study shows a predilection of male 
victims of snake bite. The age and sex incidence of 
snake bite victims throws light on the vulnerable 
section of the population. While snake bite is observed 
in all age groups, the large majority (90%) are in males 
aged 11-50 years. The predominance of male victims 
suggests a special risk of outdoor activity 12. 
In our study 8 (15%) patients presented even 
after 48 hrs of snake bite and those with features of 
systemic envenomation were having more complex 
clinical picture. The delay is due to people using folk 
and indigenous remedies before reaching the hospital 
especially in rural areas. 
There is no consensus as to the outer limit of 
time of administration of antivenom. Best effects are 
observed within four hours of bite 13. It is effective in 
symptomatic patients even when administered up to 
48 hours after bite. Reports suggest that antivenom is 
efficacious even 6-7 days after the bite 14. 
Six patients in study had clear history of snake 
bite but were asymptomatic and had no sign of 
ophitoxemia, so ASV was not given to them. 
The most obvious explanation for a confirmed 
snake-bite but no clinical manifestations are bite by a 
non-poisonous species. However, it is well 
documented that a large number of poisonous species 
also often do not cause symptoms. In a study of 432 
snake-bites in North India, Banerjee noted that 80% of 
victims showed no evidence of envenomation15. Most 
common manifestation found in study population was 
coagulopathy beside the local manifestations which 
were in almost all patients. The most common and 
earliest symptom following snake bite (poisonous or 
non poisonous) is fright16, particularly of rapid and 
unpleasant death 17 .Owing to fright, a victim attempts 
'flight' which unfortunately results in enhanced 
systemic absorption of venom. 
These emotional manifestations develop 
extremely rapidly (almost instantaneous) and may 
produce psychological shock and even death. Fear 
may cause also transient pallor, sweating and 
vomiting. Local pain with radiation and tenderness 
and the development of a small reddish wheal are the 
first to occur. This is followed by edema 13 swelling 
and appearance of bullae - all of which can progress 
quite rapidly and extensively even involving the trunk 
18. Tingling and numbness over the tongue mouth and 
scalp and paraesthesias around the wound occur 
mostly in viper bites 17. Local bleeding including 
petechial and/or purpuric rash is also seen most 
commonly with this family. 
Hematological changes are some of the 
commonest features of snake bite poisoning. Bleeding 
may occur from multiple sites including gums 19, GIT 
(haematemesis and melaena), urinary tract, injection 
sites and even as multiple petechiae and purpurae. 
Subarachnoid haemorrhages were documented in 5 of 
200 cases in Saini's series of patients in Jammu region 
20. In addition cerebral haemorrhage  and extradural 
haematoma  have also been reported 21,22 . 
The use of whole blood in dealing with viper 
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bites is common in Pakistan. Some doctors express a 
view that after 24 hours, ASV had no role and blood 
products should be used instead. However, the 
primary means of restoring clotting factors to normal 
levels is by the use of ASV. Persisting bleeding should 
prompt the administration of additional antivenom 24, 
25. Once the venom has been adequately neutralized 
with anti venom the liver will begin to restore factors 
to normal levels. Blood or blood products are only 
required in exceptional circumstances such as severe 
bleeding and should not in any eventuality be given 
until coagulation has been restored 23.  
The ASV used in our study was the liquid 
Antisnake venom produced by National Institute of 
Health Islamabad, Pakistan and in case of no 
improvement and profuse bleeding its dose was 
repeated.  
 In conclusion, snake-bite is a common life-
threatening emergency in the study area.  
Occupational risk and an increased seasonal 
incidence of snake-bite was observed.Knowledge 
of the varied clinical manifestations of snake-bite 
is important for effective management, ready 
availability and appropriate use of antisnake 
venom, close monitoring of patients, institution 
of ventilatory support and early referral to 
specialized units when required, helps in 
reducing the mortality. 
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